FDA adds vision-loss warning to every GLP-1 drug, from Ozempic to Zepbound
Nov 11, 2026
Listen to this post
read by AI voices · all episodesTHE SHORT READ
The Food and Drug Administration on Nov. 9 ordered a warning about nonarteritic anterior ischemic optic neuropathy, a rare cause of sudden vision loss, added to the labels of every GLP-1 receptor agonist.
The change covers semaglutide, tirzepatide, liraglutide, dulaglutide, the oral drug orforglipron and generic exenatide. In a meta-analysis of 126 randomized trials, the agency counted 6.4 cases per 100,000 person-years with the drugs and 3.8 with comparators; in its Sentinel cohort, the hazard ratio against DPP-4 inhibitors was 1.43.
Google Cloud opened a preview of an AI agent that works across hospitals' records and billing systems, with HCA Healthcare, Highmark Health and Northwell Health as launch partners. An international commission began a four-day review of whether the United States still meets the definition of measles elimination, and the FDA warned that connectors on some ventilator breathing tubes can detach.
THE DETAILS
- ActRegulation Nov 9, 2026
FDA asks clinicians to tell patients on GLP-1 drugs to report sudden painless vision loss in one eye immediately, per its Nov. 9 notice.
Drug makers must add nonarteritic anterior ischemic optic neuropathy to the Warnings and Precautions section of all GLP-1 receptor agonist labels, including Ozempic, Wegovy, Mounjaro, Zepbound and Foundayo, the FDA said in a Nov. 9 drug safety communication. Across 126 randomized trials with 134,253 patients, the agency counted 10 probable cases with the drugs and five with placebo, or 6.4 versus 3.8 per 100,000 person-years. In an FDA Sentinel cohort of adults with type 2 diabetes, the hazard ratio was 1.43 (95% CI, 1.02 to 2.01) against DPP-4 inhibitors and a nonsignificant 1.19 (0.91 to 1.54) against SGLT-2 inhibitors. The agency advises prompt ophthalmology referral when NAION is suspected and says to consider stopping the drug unless benefits clearly outweigh the risk; patients with a prior NAION event face a higher risk of recurrence, it said.Source: FDA drug safety communication - FYIDeployment Nov 10, 2026Google Cloud released Gemini for Healthcare in preview Nov. 10, describing it as an AI system that synthesizes medical records and reviews prior authorizations across electronic records, billing platforms, clinical guidelines and Medicare datasets under human oversight. HCA Healthcare, Highmark Health and Northwell Health are launch partners, Google said, and Fortune reported that Optum, Blue Cross Blue Shield of Massachusetts, Hartford HealthCare and Stanford School of Medicine are also launch customers. The tool can read Epic records but cannot change them and cites a source for each finding, according to Fortune. Northwell has about 400 employees who work only on insurance denials, chief executive John D'Angelo told Fortune. Google's announcement includes no outcome data.
- WatchIncident Nov 10, 2026
The Pan American Health Organization's verification commission meets Nov. 10 to 13 to judge whether measles has spread continuously in the U.S. for a year.
An independent commission appointed by the Pan American Health Organization began a closed-door review Nov. 10, running through Nov. 13, of whether the United States has had a year of continuous measles transmission, ABC News reported. A person familiar with the process told ABC News that compelling evidence of continuous spread since January 2025, when cases were first confirmed in western Texas, would be needed, and experts said genetic data may show whether outbreaks share a strain. The country has at least 5,182 confirmed cases in 2026, up from 2,289 in 2025, and 11 measles deaths over nearly two years. Canada lost its elimination status last year. Dr. Paul Offit of Children's Hospital of Philadelphia and Dr. Peter Hotez of Baylor College of Medicine told ABC News that losing the status would be largely a formality.Source: ABC News - ActIncident Nov 10, 2026
FDA says to stop using and quarantine the affected lots now and return them to Intersurgical; lot numbers are listed in the alert.
Some Intersurgical 22 mm Smoothbore breathing tubes and systems were made with too little solvent, so soft connectors can detach during use and interrupt ventilation, the FDA said in an early alert posted Nov. 10. The removal covers 11 product reference numbers, including heated-wire, monitoring-line and bilevel systems, and 38 lots. The company had received no reports of serious injury or death as of Nov. 3, when it wrote to customers; the FDA said prolonged loss of ventilation could cause hypoxic brain injury, organ failure or death.Source: FDA early alert - WatchRegulation Nov 9, 2026
Medicaid work requirements for expansion enrollees are set to take effect Jan. 1 unless a court blocks them, Healthcare Dive reported.
Oregon, Minnesota, New Mexico and Washington sued the Department of Health and Human Services in federal court over Medicaid work requirements, arguing that the Centers for Medicare & Medicaid Services lacks constitutional authority to impose them, Healthcare Dive reported Nov. 9. The rules, from the July 2025 budget law, require expansion enrollees to log 80 hours a month of work, volunteering or school to keep coverage and are set to take effect Jan. 1. The states seek preliminary and permanent injunctions against cuts to Medicaid funding. In October a judge struck down the agency's medical frailty provision and stayed enforcement of frailty determinations for six months; a bid by 25 states and the District of Columbia to pause the requirements was rejected in July, Healthcare Dive reported.Source: Healthcare Dive - FYIEvidence Nov 10, 2026Escitalopram (odds ratio 1.62; 95% CI, 1.21 to 2.18) and duloxetine (1.57; 1.08 to 2.26) produced more sustained response than fluoxetine in long-term treatment of major depressive disorder, with agomelatine (1.40; 1.06 to 1.85) also ahead, in a systematic review and network meta-analysis published Nov. 10 in The Lancet Psychiatry. The analysis drew on 115 double-blind randomized trials with 30,428 adults comparing 21 antidepressants for more than 12 weeks; the primary analysis used 35 head-to-head continuation studies with 9,888 patients. Escitalopram (OR 0.60) and duloxetine (OR 0.64) also had lower all-cause discontinuation, while bupropion and reboxetine did worse on efficacy than several other drugs. Nineteen of the 35 primary studies carried high risk of bias, and the authors said the certainty of the evidence may limit the findings' reliability.Sources: The Lancet Psychiatry, PubMed
- FYIRegulation Nov 10, 2026The FDA granted De Novo authorization to Virtuoso Surgical's system, which puts two small robotic arms at the tip of a standard endoscope, for removing bladder tumors intact rather than in fragments, creating a new classification for electromechanical systems used in endoluminal procedures, MedTech Dive reported Nov. 10. In the first 20 patients of the VIABLE study at the Chinese University of Hong Kong, detrusor muscle needed for staging was present in 94% of resected lesions, against a 60% performance goal and a median near 70% reported for conventional resection, with no intraoperative adverse events, according to MedTech Dive. The company plans a focused U.S. launch at urology centers in 2027. Dr. Sam Chang of Vanderbilt-Ingram Cancer Center, a paid consultant to the company, called the system “a meaningful new tool.”Source: MedTech Dive
- FYIRegulation Nov 10, 2026Arizona, Florida, Nebraska, Ohio and Wisconsin joined the Federal Trade Commission's lawsuit against telehealth company Hims & Hers, adding to California and Utah, the agency said Nov. 10. The amended complaint in the U.S. District Court for the Northern District of California alleges the company shared sensitive health information with advertising platforms including Meta and Snap despite promising privacy, charged for prescriptions almost immediately after patients submitted an intake form, and made subscriptions hard to cancel. The commission voted 2-0 to file it; the claims are allegations a court will decide. The FTC first brought the case in July.Source: FTC